Interim phase 2 results show carotuximab plus apalutamide sharply extends progression-free survival in metastatic castration-resistant prostate cancer, prompting earlier-use trial changes.
|Videos|July 19, 2016
Metastatic Prostate Cancer with Charles Ryan, MD and William K. Oh, MD: Case 2
Metastatic Prostate Cancer with Charles Ryan, MD and William K. Oh, MD
Advertisement
CASE: Metastatic Prostate Cancer (Part 2)
Mathew J is a 61 year old African American male who presented to his primary care physician with lower urinary tract symptoms, including sporadic hematuria. He complains of abdominal pain and low back pain starting four months ago and increasing in frequency. Prior medical history includes non-insulin dependent diabetes mellitus, well-controlled on metformin since 2006. The patient was referred to urology for further evaluation. ng/ml.
During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.
- Digital rectum exam revealed nodular prostate /L
- Serum PSA level; 129 ng/ml
- Alkaline phosphatase, 258
- TRUS/prostate biopsy: 53 gram prostate, 12/12 cores (+), Gleason 4 + 5
- CT indicates blastic lesions to lumbar spine and pelvis
- Bone Scan positive for T/L spine, pelvis, right femur, scapula
- ECOG performance status, 1
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Digital biopsy data show CAN-2409 plus radiation boosts durable lymphocyte-tumor engagement in localized prostate cancer, hinting at stronger immune surveillance and better control.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
3
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
4
Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
5